Tobramycin/fosfomycin inhalation
Alternative Names: Corus 1040; GS 9310/11; Inhaled fosfomycin/tobramycinLatest Information Update: 24 Feb 2014
At a glance
- Originator Gilead Sciences
- Class Aminoglycosides; Antibacterials; Epoxy compounds; Organophosphorus compounds; Phosphonic acids; Small molecules
- Mechanism of Action Cell wall inhibitors; Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bronchiectasis; Cystic fibrosis-associated respiratory tract infections
Most Recent Events
- 19 Feb 2014 Tobramycin/fosfomycin inhalation licensed to CURx Pharmaceuticals worldwide
- 08 Mar 2010 Gilead Sciences completes a phase II trial in Cystic fibrosis-associated respiratory tract infections in USA
- 18 Oct 2007 Phase-II clinical trials in Bronchiectasis (Cystic fibrosis related) (Inhalation)